Neurotrophic keratitis landscape improving, yet many hurdles remain

Neurotrophic keratitis is a relatively rare disease that can be difficult to manage, and treatment varies depending on disease stage.
In recent years, the development of Oxervate (cenegermin-bkbj ophthalmic solution 0.002%, Dompé U.S.) has transformed the treatment landscape, becoming one of the greatest advancements for patients with neurotrophic keratitis, according to Cory J. Lappin, OD, MS, FAAO, an optometrist at Phoenix Eye Care and the Dry Eye Center of Arizona.

Related Keywords

Phoenix ,Arizona ,United States ,Heather Biele ,Claris Biotherapeutics ,Byjennifer Southall ,Coryj Lappin ,Eye Center ,Phoenix Eye Care ,Dry Eye Center ,Prokera Slim ,Enriched Tear Film Gene Therapy ,